Haertel Franz, Babst Josephine, Bruening Christiane, Bogoviku Jurgen, Otto Sylvia, Fritzenwanger Michael, Gecks Thomas, Ebelt Henning, Moebius-Winkler Sven, Schulze P Christian, Pfeifer Ruediger
Department of Cardiology and Intensive Care, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany.
Department of Cardiology and Intensive Care, University Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120 Halle (Saale), Germany.
J Clin Med. 2023 Apr 21;12(8):3015. doi: 10.3390/jcm12083015.
Hemolysis, a common adverse event associated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO), may affect neuron-specific enolase (NSE) levels and potentially confound its prognostic value in predicting neurological outcomes in resuscitated patients without return of spontaneous circulation (ROSC) that require extracorporeal cardiopulmonary resuscitation (eCPR). Therefore, a better understanding of the relationship between hemolysis and NSE levels could help to improve the accuracy of NSE as a prognostic marker in this patient population.
We retrospectively analyzed the records of patients who received a VA-ECMO for eCPR between 2004 and 2021 and were treated in the medical intensive care unit (ICU) of the University Hospital Jena. The outcome was measured clinically by using the Cerebral Performance Category Scale (CPC) four weeks after eCPR. The serum concentration of NSE (baseline until 96 h) was analyzed by enzyme-linked immunosorbent assay (ELISA). To evaluate the ability of individual NSE measurements to discriminate, receiver operating characteristic (ROC) curves were calculated. Serum-free hemoglobin (fHb, baseline until 96 h) served as a marker for identifying a confounding effect of parallel hemolysis.
190 patients were included in our study. A total of 86.8% died within 4 weeks after ICU admission or remained unconscious (CPC 3-5), and 13.2% survived with a residual mild to moderate neurological deficit (CPC 1-2). Starting 24h after CPR, NSE was significantly lower and continued to decrease in patients with CPC 1-2 compared to the group with an unfavorable outcome of CPC 3-5. In addition, when evaluating on the basis of receiver operating characteristic curves (ROC), relevant and stable area under the curve (AUC) values for NSE could be calculated (48 h: 0.85 // 72 h: 0.84 // 96 h: 0.80; < 0.01), and on the basis of a binary logistic regression model, relevant odds ratios for the NSE values were found even after adjusting for fHb regarding the prediction of an unfavorable outcome of CPC 3-5. The respective adjusted AUCs of the combined predictive probabilities were significant (48 h: 0.79 // 72 h: 0.76 // 96 h: 0.72; ≤ 0.05).
Our study confirms NSE as a reliable prognostic marker for poor neurological outcomes in resuscitated patients receiving VA-ECMO therapy. Furthermore, our results demonstrate that potential hemolysis during VA-ECMO does not significantly impact NSE's prognostic value. These findings are crucial for clinical decision making and prognostic assessment in this patient population.
溶血是与静脉-动脉体外膜肺氧合(VA-ECMO)相关的常见不良事件,可能影响神经元特异性烯醇化酶(NSE)水平,并可能混淆其在预测需要体外心肺复苏(eCPR)且未恢复自主循环(ROSC)的复苏患者神经学预后方面的预后价值。因此,更好地了解溶血与NSE水平之间的关系有助于提高NSE作为该患者群体预后标志物的准确性。
我们回顾性分析了2004年至2021年间在耶拿大学医院医学重症监护病房(ICU)接受VA-ECMO进行eCPR的患者记录。在eCPR四周后,使用脑功能表现分类量表(CPC)对结果进行临床评估。通过酶联免疫吸附测定(ELISA)分析NSE的血清浓度(基线至96小时)。为了评估个体NSE测量的鉴别能力,计算了受试者操作特征(ROC)曲线。无血清血红蛋白(fHb,基线至96小时)用作识别平行溶血混杂效应的标志物。
我们的研究纳入了190例患者。共有86.8%的患者在入住ICU后4周内死亡或仍昏迷(CPC 3-5),13.2%的患者存活但有轻度至中度神经功能缺损(CPC 1-2)。与CPC 3-5不良结局组相比,CPC 1-2组患者在心肺复苏后24小时开始,NSE显著降低且持续下降。此外,在基于受试者操作特征曲线(ROC)进行评估时,可以计算出NSE的相关且稳定的曲线下面积(AUC)值(48小时:0.85 // 72小时:0.84 // 96小时:0.80;P < 0.01),并且基于二元逻辑回归模型,即使在调整fHb后,关于CPC 3-5不良结局的预测,NSE值的相关优势比仍然存在。联合预测概率的各自调整后AUC具有显著性(48小时:0.79 // 72小时:0.76 // 96小时:0.72;P ≤ 0.05)。
我们的研究证实NSE是接受VA-ECMO治疗的复苏患者神经功能不良预后的可靠预后标志物。此外,我们的结果表明VA-ECMO期间潜在的溶血不会显著影响NSE的预后价值。这些发现对于该患者群体的临床决策和预后评估至关重要。